Table 1 Baseline characteristics
Baseline characteristics | Placebo (n = 8) | Dapagliflozin 10 mg (n = 8) | P value |
|---|---|---|---|
Male sex, N (%) | 5 (62.5) | 8 (100) | |
Age, years | 67 ± 2.2 | 66 ± 2.6 | P = 0.7 |
Diabetes duration, years | 8.25 ± 0.6 | 6.3 ± 1.0 | P = 0.2 |
HbAlc, % | 8.1 ± 0.2 | 7.8 ± 0.1 | P = 0.45 |
Fasting glycemia (mg/dl) | 136 ± 17 | 140 ± 12 | P = 0.5 |
C-peptide (ng/ml) | 1.4 ± 0.3 | 1.7 ± 0.2 | P = 0.6 |
BMI, kg/m2 | 28.5 ± 1.0 | 27.3 ± 1.1 | P = 0.3 |
Body weight, kg | 81.8 ± 4.7 | 81.8 ± 2.6 | P > 0.9 |
Heart rate, bpm | 61 ± 4 | 65 ± 4 | P = 0.9 |
Systolic BP, mmHg | 135 ± 5.2 | 143 ± 5.1 | P = 0.2 |
Diastolic BP, mmHg | 71 ± 3.8 | 68 ± 4.4 | P = 0.4 |
CAD (previous PCl/no PCI) | 4/4 | 3/5 | P = 0.3 |
eGFR (ml/min) | 90.6 ± 3.1 | 85.8 ± 6.2 | P = 0.5 |
Medications | |||
Metformin | 8 (100) | 7 (87.5) | |
DPP- 4i | 4 (50) | 3 (37.5) | |
GLP-1RA | 2 (25) | 1 (12.5) | |
Basal insulin | 2 (25) | 3 (37.5) | |
Sulfonylurea | 2 (25) | 1(12.5) |